(New York) – The Rosen Law Firm announced on April 11, 2026, an investigation into potential securities claims against OS Therapies Incorporated (OSTX), alleging the company may have provided materially misleading business information to investors.
"If you purchased OS Therapies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement," the law firm stated in a press release.
The investigation stems from allegations that OS Therapies may have issued materially misleading business information to the investing public. The Rosen Law Firm, a global investor rights law firm, is encouraging investors who purchased OSTX securities to inquire about the securities class action investigation.
The announcement of the investigation could create downward pressure on the OSTX stock price and increase its volatility. The investigation may lead to a formal class-action lawsuit, which could result in significant legal costs and potential financial penalties for OS Therapies.
This article is for informational purposes only and does not constitute investment advice.
